Vivek Subbiah

Read more about this approval here

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

A report of two patients with advanced tumors harboring alterations in the RET gene who responded to treatment with the selective inhibitor LOXO-292 highlights that the clinical actionability of RET mutations, say researchers.

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.